Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
ConditionIgA Nephropathy (IgAN)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWaid City Hospital, Zurich
About this trial
An observational study tracking the clinical course of patients with IgA nephropathy.
Eligibility criteria
Qualifiers
IgA Nephropathy, Use of Sparsentan
Disqualifiers
age < 18y
Trial design
Treatments tested in this trial
- sparsentan
- sparsentan
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov